[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

107

1 MR. DOBSON: -- has not been established
2 otherwise, although they have been tested in lower
3 details at the same time, I think.
4 CO-CHAIRMAN FAUCI: Right. Within the
5 framework of the study, it's safe. Certainly, you
6 can't make any universal projection from that. It's
7 a good point, Jesse.
8 I just wanted to establish that. Now we
9 could leave it open for any questions or --
10 CO-CHAIRMAN CARPENTER: Yes. We're now
11 open for any questions or comments. Yes, Larry?
12 DISCUSSION OF QUESTIONS
13 DR. BROWN: Is it possible that we can get
14 some information with respect to the demography of the
15 patients accrued in these trials, and particularly the
16 HIV behavior groups?
17 Dan had talked about the importance of
18 looking at patients at different levels of CD4 counts
19 and looking at children and adults, but in a patient
20 population that is, in fact, driving HIV in this
21 country, drug users, would also be important given
22 their background immune dysfunction.
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]